Όλο το DSpace

Εμφάνιση απλής εγγραφής

Lipid-lowering treatment in peripheral artery disease

dc.creatorKatsiki N., Giannoukas A.D., Athyros V.G., Mikhailidis D.P.en
dc.date.accessioned2023-01-31T08:33:46Z
dc.date.available2023-01-31T08:33:46Z
dc.date.issued2018
dc.identifier10.1016/j.coph.2018.01.003
dc.identifier.issn14714892
dc.identifier.urihttp://hdl.handle.net/11615/74639
dc.description.abstractPeripheral artery disease (PAD) is characterized by increased cardiovascular (CV) risk, limb morbidity and all-cause mortality. According to the current guidelines (2016) of the American Heart Association/American College of Cardiology on the management of PAD patients, statin therapy is recommended for PAD patients in order to treat dyslipidemia and reduce CV risk. The present narrative review discusses the use of statins and other lipid-lowering drugs such as ezetimibe, fibrates, niacin, anacetrapib and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in PAD patients in terms of both CV and limb outcomes. The clinical implications of hypolipidemic drug therapy in special patient populations including those with metabolic syndrome, non-alcoholic fatty liver disease, chronic kidney disease and type 2 diabetes mellitus, which may frequently co-exist with PAD, are also considered. © 2018 Elsevier Ltden
dc.language.isoenen
dc.sourceCurrent Opinion in Pharmacologyen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85041696307&doi=10.1016%2fj.coph.2018.01.003&partnerID=40&md5=07df87b1c61f61837c21c0bfdd225e6f
dc.subjectalirocumaben
dc.subjectanacetrapiben
dc.subjectantilipemic agenten
dc.subjectatorvastatinen
dc.subjectbezafibrateen
dc.subjectcholesterol ester transfer protein inhibitoren
dc.subjectdalcetrapiben
dc.subjectevacetrapiben
dc.subjectevolocumaben
dc.subjectezetimibeen
dc.subjectfenofibrateen
dc.subjectfibric acid derivativeen
dc.subjecthydroxymethylglutaryl coenzyme A reductase inhibitoren
dc.subjectnicotinic aciden
dc.subjectproprotein convertase 9 inhibitoren
dc.subjectrosuvastatinen
dc.subjectserine proteinase inhibitoren
dc.subjectsimvastatinen
dc.subjecttorcetrapiben
dc.subjectunclassified drugen
dc.subjectantilipemic agenten
dc.subjectCETP protein, humanen
dc.subjectcholesterol ester transfer proteinen
dc.subjectPCSK9 protein, humanen
dc.subjectproprotein convertase 9en
dc.subjectcardiovascular risken
dc.subjectchronic kidney failureen
dc.subjectcomorbidityen
dc.subjectcritical limb ischemiaen
dc.subjectEuropean Medicines Agencyen
dc.subjectfood and drug administrationen
dc.subjecthumanen
dc.subjectmetabolic syndrome Xen
dc.subjectnon insulin dependent diabetes mellitusen
dc.subjectnonalcoholic fatty liveren
dc.subjectnonhumanen
dc.subjectoutcome assessmenten
dc.subjectperipheral occlusive artery diseaseen
dc.subjectpriority journalen
dc.subjectReviewen
dc.subjectrisk assessmenten
dc.subjectrisk reductionen
dc.subjectanimalen
dc.subjectantagonists and inhibitorsen
dc.subjectperipheral occlusive artery diseaseen
dc.subjectAnimalsen
dc.subjectCholesterol Ester Transfer Proteinsen
dc.subjectEzetimibeen
dc.subjectFibric Acidsen
dc.subjectHumansen
dc.subjectHypolipidemic Agentsen
dc.subjectNiacinen
dc.subjectPeripheral Arterial Diseaseen
dc.subjectProprotein Convertase 9en
dc.subjectElsevier Ltden
dc.titleLipid-lowering treatment in peripheral artery diseaseen
dc.typeotheren


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής